

1 **Supplementary Information for:**

2

3 **Engineering multiple species-like genetic incompatibilities in insects**

4

5

6 **Maselko et al.**

7

8

9 **This PDF file includes:**

10

11 Supplementary Figures 1 to 10

12 Supplementary Tables 1 to 4

13 References

14


15

16

17

18

19




20

21 **Supplementary Figure 1. Promoter mutation characterization.** Promoter mutant sequencing traces and
 22 alignments to wild-type promoters. Targeted protospacers indicated in red and PAMs indicated in blue.

23


24



Supplementary Figure 2. Crossing strategy to produce *hh*-EGI flies. (A.) Genotypes and sex of flies involved in crosses required to bring together EGI components. Crosses are indexed with numbered white circles. ‘X’ designates a recombination event required in the female parent of cross #9. The female from cross #18 resulted from cross #7 (not cross #5). Embryos from cross #13 were injected with promoter::dCas9::VPR constructs and $\Phi C31$ integrase. Question mark denotes a chromosome genotype that was not verified. (B.) Illustrated and color-coded genotypes of key intermediates. BDSC #54591, BDSC #67560, and BDSC #9744 were purchased from the Bloomington Drosophila Stock Center. Star ST, SGSB, and C26b are balancer strains.

25

26




Supplementary Figure 3. Crossing strategy to produce *wg*-EGI flies. (A.) Genotypes and sex of flies involved in crosses required to bring together EGI components. Crosses are indexed with numbered white circles. 'X' designates a recombination event required in the female parent of cross #7. Embryos from cross #1 were injected with a sgRNA-*wg* construct and Φ C31 integrase. Question mark denotes a chromosome genotype that was not verified. The males in crosses #7, 8, and 11 and the female in cross #4 are offspring from Supplementary Figure 6, cross #4. The female in cross #11 is offspring from Supplementary Figure 2, cross #16. (B.) Illustrated and color-coded genotypes of key intermediates. BDSC #9748 was purchased from the Bloomington Drosophila Stock Center. Star ST is a balancer strain.

27

28


29




Supplementary Figure 4. Rejection strategy to produce *hh*-EGI flies. (A.) Genotypes and sex of flies involved in crosses required to bring together EGI components. Crosses are indexed with numbered white circles. Embryos from cross #8 were injected with promoter::dCas9::VPR + sgRNA-*hh* constructs and ΦC31 integrase. Question mark denotes a chromosome genotype that was not verified. (B.) Illustrated and color-coded genotypes of key intermediates. BDSC #54591, BDSC #67560, and BDSC #9752 were purchased from the Bloomington Drosophila Stock Center. Star ST, SGSB, and C26b are balancer strains.

30

31



Supplementary Figure 5. Reinjection strategy to produce *pyr*-EGI flies. (A.) Genotypes and sex of flies involved in crosses required to bring together EGI components. Crosses are indexed with numbered white circles. Embryos from cross #8 were injected with promoter::dCas9:VPR + sgRNA-*pyr* constructs and ΦC31 integrase. Question mark denotes a chromosome genotype that was not verified. (B.) Illustrated and color-coded genotypes of key intermediates. BDSC #54591, BDSC #67537, and BDSC #9748 were purchased from the Bloomington Drosophila Stock Center. Star ST, SGSB, and C26b are balancer strains.




Supplementary Figure 6. Reinjection strategy to produce *wg*-EGI flies. (A.) Genotypes and sex of flies involved in crosses required to bring together EGI components. Crosses are indexed with numbered white circles. Embryos from cross #1 were injected with the sgRNA-*wg* expression construct. Embryos from cross #7 were injected with promoter::dCas9::VPR + sgRNA-*wg* constructs and Φ C31 integrase. Question mark denotes a chromosome genotype that was not verified. The male in cross #5 is offspring from Supplementary Figure 5, cross #7. (B.) Illustrated and color-coded genotypes of key intermediates. BDSC #51324 was purchased from the Bloomington Drosophila Stock Center. *yGlaC* and *SGSB* are balancer strains.

34

35


36



Supplementary Figure 7: Chromosomal maps of all EGI strains reported in this work.

37


38



Supplementary Figure 8: Immunohistochemistry of dissected brains. (A.) Chromosomal locations of genome alterations for EGI strains whose hybrid offspring were analysed by immunohistochemistry. EGI strains illustrated here correspond to those used in Figure 3. (B.) Immunofluorescence staining of 3rd instar larval brains from wild-type (left) or hybrid (right) showing over- or ectopic-expression of targeted signalling pathways. Grayscale images show antibody staining for proteins encoded by lethal overexpression target (*wingless*, top) or downstream signalling pathway components (p-*ERK1/2*, middle and *patched*, bottom). Corresponding brightfield images of the brains to the right. Scale bar = 200 μ m. Images are representative of at least six independent biological replicates for each strain.


39

40



41

42 **Supplementary Figure 9: Fecundity of EGI and WT strains when self-mated.** Average adult offspring resulting
 43 from three matings between two males and three females of the same strain. Strains are in the same order and
 44 contain the same data as in the mating compatibility assay (Figure 4). Error bars denote one standard deviation
 45 across three replicates, unless otherwise stated. Hh.Foxo.Cross had no replicates. Pyr.Tub.Injection contained
 46 only 1 replicate. Pyr.Wg.Injection, Wg.Foxo.Injection, and Wg.Wg.Cross contained 2 replicates each.
 47



Supplementary Figure 10: Iterative release scheme for negatively correlating cross resistance. Purple denotes wild-type pests, green and yellow denote mutually-incompatible EGI strains, for which only males would be released. Orange denotes resistant 'escapees', which inherit half of their genome from the previously released biocontrol EGI strain.

48

49

Supplementary Table 1: Promoter Target Sequences

Target Promoter	Target 1	Target 2	Reference
<i>hh</i>	TATGCCACTCGACGTTTCGAT CGG	TTCCAATTCCCTTGCGCATA AGG	1
<i>hid</i>	CACATGCACGTGCATGA AGG	CATGCACGTGCATGAAGG AGG	2
<i>pyr</i>	CGGCGGGGGCGGTTTCGAAGC GGG	CGCCGCCGACAATCCGAATG CGG	1
<i>upd1</i>	GCGAGCTGAGCGGCCTCTGC CGG	TGCCGACGAGCGGTACGCCA TGG	1
<i>upd2</i>	CAGCAAGCGATTGTGATAGT TGG	TGCTGATGCTGATCGCTCCA CGG	1
<i>upd3</i>	TGGAGTGGAGTGTGTGGAG TGG	GGAGTTCAGTCAGTCTCCGC CGG	1
<i>vn</i>	AGCATTCAACGTATCTCA CGG	GTGCCGAAGATATTCGAACA CGG	1
<i>wg</i>	ATGAGGTTGCGCAAATAATC GGG	GGAAATGGAAAACTCTGCC CGG	3

Supplementary Table 2: *D. melanogaster* strains used in this study

Strain	Description	Reference	BDSC #
Wild Type	Oregon R	4	N/A
White Eye	w ¹¹¹⁸	5	5905
3 rd Chr. attP9	y ¹ w ¹¹¹⁸ ; ; PBac{y[+]-attP-9A}VK00027	6	9744
3 rd Chr. attP3	y ¹ w ¹¹¹⁸ ; PBac{y[+]-attP-3B}VK00031	6	9748
2 nd Chr. attP3	y ¹ w ¹¹¹⁸ ; PBac{y[+]-attP-3B}VK00037	6	9752
Vas-Cas9	w[1118]; PBac{y[+mDint2]=vas-Cas9}VK00027	7	51324
2 nd Chr. attP3, ΔHH ³⁰¹	w ¹¹¹⁸ ; PBac{y[+]-attP-3B}VK00037; ΔHH ³⁰¹	this study	
3 rd Chr. attP3, Δpyr ³³⁷	w ¹¹¹⁸ ; Δpyr ³³⁷ ; PBac{y[+]-attP-3B}VK00031	this study	
3 rd Chr. attP3, ΔWg ^{C1}	w ¹¹¹⁸ ; ΔWg ^{C1} ; PBac{y[+]-attP-3B}VK00031	this study	
2 nd Chr. bal, ΔHH ³⁰¹	w ¹¹¹⁸ ; Sp1/ CyO; ΔHH ³⁰¹	this study	
3 rd Chr. bal, Δpyr ³³⁷	w ¹¹¹⁸ ; Δpyr ³³⁷ ; TM2/ TM6b, Tb, Hu	this study	
3 rd Chr. bal, ΔWg ^{C1}	w ¹¹¹⁸ ; ΔWg ^{C1} ; Sb/ TM6b, Tb, Hu	this study	
hh.FoxO.cross	w ¹¹¹⁸ ; P{y[+t7.7] v[+t1.8]=TOE.GS00191}attP40; P{pFoxo::dCas9-VPR}attP-9A, ΔHH ³⁰¹	this study	
hh.FoxO.injection	y ¹ w ¹¹¹⁸ ; P{pFoxo::dCas9-VPR::sgRNA ^{HH} }attP-3B; ΔHH ³⁰¹	this study	
hh.Tub.cross	w ¹¹¹⁸ ; P{y[+t7.7] v[+t1.8]=TOE.GS00191}attP40; P{pTub::dCas9-VPR}attP-9A, ΔHH ³⁰¹	this study	
hh.Tub.injection	y ¹ w ¹¹¹⁸ ; P{pTub::dCas9-VPR::sgRNA ^{HH} }attP-3B; ΔHH ³⁰¹	this study	
pyr.Bam.injection	w ¹¹¹⁸ ; Δpyr ³³⁷ ; P{pBam::dCas9-VPR::sgRNA ^{Pyr} }attP-3B	this study	
pyr.FoxO.injection	w ¹¹¹⁸ ; Δpyr ³³⁷ ; P{pFoxo::dCas9-VPR::sgRNA ^{Pyr} }attP-3B	this study	
pyr.Tub.injection	w ¹¹¹⁸ ; Δpyr ³³⁷ ; P{pTub::dCas9-VPR::sgRNA ^{Pyr} }attP-3B	this study	
pyr.Wg.injection	w ¹¹¹⁸ ; Δpyr ³³⁷ ; P{pΔWg ^{C1} ::dCas9-VPR::sgRNA ^{Pyr} }attP-3B	this study	
wg.FoxO.cross	w ¹¹¹⁸ ; P{sgRNA ^{Wg} }attP-3B, ΔWg ^{C1} ; P{pFoxo::dCas9-VPR}attP-9A	this study	
wg.FoxO.injection	y ¹ w ¹¹¹⁸ ; ΔWg ^{C1} ; P{pFoxo::dCas9-VPR::sgRNA ^{Wg} }attP-3B	this study	
wg.Wg.cross	w ¹¹¹⁸ ; PBac{sgRNA ^{Wg} }attP-3B, ΔWg ^{C1} ; P{pΔWg ^{C1} ::dCas9-VPR}attP-9A	this study	
wg.Wg.injection	y ¹ w ¹¹¹⁸ ; ΔWg ^{C1} ; P{pΔWg ^{C1} ::dCas9-VPR::sgRNA ^{Wg} }attP-3B	this study	
nos-Cas9	y ¹ M{w[+mC]=nos-Cas9.P}ZH-2A, w [*]	8	54591
hh sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00191}attP40	1	67560
hid sgRNA	y ¹ w ¹¹¹⁸ ; PBac{sgRNA ^{Hid} }attP-3B	this study	
pyr sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00085}attP40	1	67537
upd1 sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00169}attP40	1	67555
upd2 sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00171}attP40	1	67556
upd3 sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00129}attP40	1	67546
vn sgRNA	y ¹ sc [*] v ¹ ; P{y[+t7.7] v[+t1.8]=TOE.GS00144}attP40	1	67548
wg sgRNA	y ¹ w ¹¹¹⁸ ; ; PBac{sgRNA ^{Wg} }attP-3B	this study	
pTub::dCas9-VPR	y ¹ w ¹¹¹⁸ ; ; P{pTub::dCas9-VPR}attP-9A	this study	
pFoxo::dCas9-VPR	y ¹ w ¹¹¹⁸ ; ; P{pFoxo::dCas9-VPR}attP-9A	this study	
pTub::dxCas9-VPR	y ¹ w ¹¹¹⁸ ; ; P{pTub::dxCas9-VPR}attP-9A	this study	
pΔWg::dCas9-VPR	y ¹ w ¹¹¹⁸ ; ; P{pΔWg ^{C1} ::dCas9-VPR}attP-9A	this study	
ΔWg	w ¹¹¹⁸ ; ΔWg ^{C1}	this study	
ΔHH	w ¹¹¹⁸ ; ; ΔHH ³⁰¹	this study	
ΔPyr	w ¹¹¹⁸ ; ΔPyr ³³⁷	this study	

Supplementary Table 3: Plasmids used in this study

Plasmid	Integrated in Fly Strain	Description	Reference/ GenBank Accession #
pMM7-1-1	N/A	pU6-BbsI-chiRNA targeting upstream wg promoter protospacer	this study
pMM7-1-2	N/A	pU6-BbsI-chiRNA targeting downstream wg promoter protospacer	this study
pMM7-5-3	wg sgRNA wg.FoxO.cross	Expresses dual sgRNAs targeting Wg promoter	this study
pMM7-6-1	N/A	dCas9-VPR plasmid. Promoters cloned into NotI restriction site.	this study/ MT882253
pMM7-6-2	hh.FoxO.cross wg.FoxO.cross wg.Wg.cross	Foxo promoter driving dCas9-VPR expression	this study
pMM7-6-3	pTub::dCas9-VPR hh.Tub.cross	Short tubulin alpha promoter driving dCas9-VPR expression	this study
pMM7-6-4	pΔWg ^{C1} ::dCas9-VPR wg.Wg.cross	Mutated Wg promoter driving dCas9-VPR expression	this study
pMM7-9-1	N/A	dxCas9-VPR plasmid. Promoters cloned into NotI restriction site.	this study/ MT882254
pMM7-9-4	pTub::dxCas9-VPR	Short tubulin alpha promoter driving dxCas9-VPR expression	this study
pMM7-6-2-HH	hh.FoxO.injection	Foxo promoter driving dCas9-VPR expression. Dual sgRNAs targeting HH promoter.	this study
pMM7-6-2-Pyr	pyr.FoxO.injection	Foxo promoter driving dCas9-VPR expression. Dual sgRNAs targeting Pyr promoter.	this study
pMM7-6-2-Wg	wg.FoxO.injection	Foxo promoter driving dCas9-VPR expression. Dual sgRNAs targeting Wg promoter.	this study
pMM7-6-3-HH	hh.Tub.injection	Short tubulin alpha promoter driving dCas9-VPR expression. Dual sgRNAs targeting HH promoter.	this study
pMM7-6-3-Pyr	pyr.Tub.injection	Short tubulin alpha promoter driving dCas9-VPR expression. Dual sgRNAs targeting Pyr promoter.	this study
pMM7-6-4-Pyr	pyr.Wg.injection	Mutated Wg promoter driving dCas9-VPR expression. Dual sgRNAs targeting Pyr promoter.	this study
pMM7-6-4-Wg	wg.Wg.injection	Mutated Wg promoter driving dCas9-VPR expression. Dual sgRNAs targeting Wg promoter.	this study
pMM7-6-5-Pyr	pyr.Bam.injection	Bam promoter driving dCas9-VPR expression. Dual sgRNAs targeting Pyr promoter.	this study
pU6-BbsI-chiRNA	N/A	sgRNA expression plasmid	7
pAct:dCas9-VPR	N/A	Source of dCas9-VPR	9
pCFD4	N/A	sgRNA expression plasmid	8
p{CFD4-3xP3::DsRed}	N/A	sgRNA expression plasmid	10

Supplementary Table 4: Primer Sequences

Name	Sequence (5' -> 3')	Notes
MM_2step_dCas_F	ctggtctagagcccgggGCTAGCCAATTCTATATTCTAAAAACA C	Amplifies dCas9-VPR from pAct:dCas9-VPR
MM_2step_dCas_R	ctgattatgatctagagtcgGTCAAACAGAGATGTGT	
MM_bgl_SVT_F	tctggtctagagcccgggGCTAGCcgactctagatcataatcag	Amplifies SV40 terminator from ph-Stinger
MM_bgl_SVT_R	cggggtaccggcgccggcgtaagatacattgatgagtttg	
MM_pFoxo_F	ACGTAAGTACTGTCTGCAGCGTAAGCTTCGTACGTAGC gtcaaattggtgtgattac	Amplifies Foxo promoter and 5'UTR
MM_pFoxo_R	AGCCAATGGAGTACTTCTGTCCATtttgaagattGC tccaattcgcttttattcg	
MM_sptuba_F2	GCAGCGTAAGCTTCGTACGTAGCgaccgtctcaaagtactgctT	Amplifies portion of tubulin promoter and 5' UTR
MM_sptuba_R	GGAGTACTTCTGTCCATtttgaagattGCattggaagtgtttcacacgc gac	
MM_pWgdCas_F	ACGTAAGTACTGTCTGCAGCGTAAGCTTCGTACGTAGC cagctcctgttggtgac	Amplifies wingless promoter and 5' UTR
MM_pWgdCas_R	AGCCAATGGAGTACTTCTGTCCATtttgaagattGC gctgatcgggttatctgttc	
MM_pBam_F	ACGTAAGTACTGTCTGCAGCGTAAGCTTCGTACGTAGC actctaaaacgtaaagaac	Amplifies bam promoter and 5'UTR
MM_pBam_R	AGCCAATGGAGTACTTCTGTCCATtttgaagattGC cttaagttaaatcacacaaa	
MM_2wg_F	AGATATCCGGGTGAACTTCG ATGAGGTTGCGCAAATAATC GTTTTAGAGCTAGAAATAGC	Primers to clone wingless spacers into p{CFD4-3xP3::DsRed}
MM_2wg_R	GCTATTTCTAGCTCTAAAAC GGCAGAGTTTTTCCATTTC CGACGTAAATTGAAAATAG	
MM_dmsgRNA_F	tcttaGCGGCTCGAGGGTACAAGCCGAATTGATCCACTAG	Amplifies sgRNA cassettes.

MM_dmsgRNA	TAGTGGATCTCTAGAGGTACATAATAAATACTGGCGAAAGC	
<u>Promoter sequencing</u>		
HH_F	CCAGGAGTCACACAATACAC	Hedghog promoter
HH_R	GCGAATACGAATGCGAGTAT	Hedghog promoter
Pyr_F	GAACGAACTGGCCCACTTGG	Pyramus promoter
Pyr_R	CTGTAGCCGCGCAATGCACT	Pyramus promoter
Wg_F	CGGAATGCCAAAGTGTGT	Wingless promoter
Wg_R	GCTAGTTATAGATCGGTTTCGATC	Wingless promoter

Primers and gBlock to generate dXCas9-VPR

MM_xCas1_F2	ACGTAAGTACTGTCTGCAGCGTAAGCTTCGTACGTAGCGGCCGCaatcttataaaaATGGAC AAGAAGTACTCCATTG
MM_xCas1_R	GTAGGTGTCTTTGCTCAGTTGAAGCTTGGTATCTTCGGCCAGG TCGAA
MM_xCas2_F	TCCGATGGATTTGCCAACCCGGAACCTTCATTGATTCAGTTGATCCATG ATGACTCTCTC
MM_xCas2_R	CTCGTTACCTTTCTGCAGCACGCCCGCACTAGCGA
MM_xCas3_F	CGAATGCTCGCTAGTGCGGGCGTGCTGCAGAAAGGTAACGA G
MM_xCas3_R	tgattatgatctagagtcggTCAAAACAGAGATGTGTCTGAAG
MM_xCas4_F	TTCGACACATCTCTGTTTTGAccgactctagatcataatc
MM_xCas4_R	ACACTAGTGGATCTCTAGAGGTACCCTCGAGCCGCTaagatacat tgatgagttt

55 MM_gdXCas9
56 ACCAAGCTTCAACTGAGCAAAGACACCTACGATGATGATCTCGACAATCTGCTGGCCAGATCGGGC
57 ACCAGTACGCAGACCTTTTTTGGCGCAAAGAACCTGTCAGACGCCATTCTGCTGAGTGATATTCTG
58 CGAGTGAACACGGAGATCACAAAGCTCCGCTGAGCGTAGTATGATCAAGCTCTATGATGAGCACC
59 ACCAAGACTTGACTTTGCTGAAGGCCCTTGTGAGACAGCAACTGCCTGAGAAGTACAAGGAAATTTT
60 CTTGATCAGTCTAAAAATGGCTACGCCGATACATTGACGGCGGAGCAAGCCAGGAGGAATTTTAC
61 AAATTTATTAAGCCCCTTTGGAAAAAATGGACGGCACCGAGGAGCTGCTGGTAAAGCTTAACAGAG
62 AAGATCTGTTGCGCAAACAGCGCACTTTGACAATGGAATCATCCCCACCAGATTCACCTGGGCGA
63 ACTGCACGCTATCCTCAGGCGGCAAGAGGATTTCTACCCCTTTTTGAAAGATAACAGGGAAAAGATT
64 GAGAAAATCCTCACATTTCCGATACCCTACTATGTAGGCCCCCTCGCCCGGGGAAATTCAGATTCCG
65 GTGGATGACTCGAAATCAGAAGAAACCATCACTCCCTGGAACCTCGAGAAAGTCGTGGATAAGGG
66 GGCCTTGCCAGTCCTTCATCGAAAGGATGACTAATTTGATAAAAATCTGCTAACGAAAAGGTGC
67 TTCCTAAACTCTCTGCTGTACGAGTACTTCACAGTTTATAACGAGCTACCAAGGTCAAATACGTCA
68 CAGAAGGGATGAGAAAGCCAGCATTCTGTCTGGAGATCAGAAGAAAGCTATCGTGGACCTCCTCTT
69 CAAGACGAACCGAAAGTTACCGTGAACAGCTCAAAGAAGACTATTTCAAAAAGATTGAATGTTTC
70 GACTCTGTTGAAATCAGCGGAGTGGAGGATCGCTTCAACGCATCCCTGGGAACGTATCACGATCTCC
71 TGA AAAATCATTAAAGACAAGGACTTCTGGACAATGAGGAGAACGAGGACATTCTTGAGGACATTGT
72 CCTACCCCTTACGTTGTTTGAAGATAGGGAGATGATTGAAGAACGCTTGAAAACCTACGCTCATCTCT
73 TCGACGACAAAGTCATGAAACAGCTCAAGAGGCGCCGATATACAGGATGGGGGCGGCTGTCAAGAA
74 AACTGATCAATGGGATCCGAGACAAGCAGAGTGGAAAGACAATCCTGGATTTTCTTAAGTCCGATGG
75 ATTTGCCAACCCGGAACCTTCATT
76

77

78

79 **Supplementary References**

- 80 1. Ewen-Campen, B. *et al.* Optimized strategy for in vivo Cas9-activation in *Drosophila*. *Proc.*
81 *Natl. Acad. Sci.* 201707635 (2017). doi:10.1073/pnas.1707635114
- 82 2. Waters, A. J. *et al.* Rationally-engineered reproductive barriers using CRISPR & CRISPRa: an
83 evaluation of the synthetic species concept in *Drosophila melanogaster*. *Sci. Transl. Med.*
84 (2018). doi:10.1101/259010
- 85 3. Lin, S., Ewen-Campen, B., Ni, X., Housden, B. E. & Perrimon, N. In vivo transcriptional
86 activation using CRISPR/Cas9 in *Drosophila*. *Genetics* **201**, 433–442 (2015).
- 87 4. Lindsley, D. L., Grell, E. H. & Bridges, C. B. (Calvin B. *Genetic variations of Drosophila*
88 *melanogaster*. (1967).
- 89 5. Ryder, E., Hartl, D. L. & Wu, C. -tin. The DrosDel Collection: A Set of P-Element Insertions for
90 Generating Custom Chromosomal Aberrations in *Drosophila melanogaster*. *Genetics* **167**,
91 797–813 (2004).
- 92 6. Venken, K. J. T., He, Y., Hoskins, R. A. & Bellen, H. J. P[acman]: a BAC transgenic platform for
93 targeted insertion of large DNA fragments in *D. melanogaster*. *Science* **314**, 1747–51 (2006).
- 94 7. Gratz, S. J. *et al.* Genome engineering of *Drosophila* with the CRISPR RNA-guided Cas9
95 nuclease. *Genetics* **194**, 1029–1035 (2013).
- 96 8. Port, F., Chen, H. M., Lee, T. & Bullock, S. L. Optimized CRISPR/Cas tools for efficient germline
97 and somatic genome engineering in *Drosophila*. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E2967-76
98 (2014).
- 99 9. Chavez, A. *et al.* Comparison of Cas9 activators in multiple species. *Nat. Methods* **13**, 563–7
100 (2016).
- 101 10. Stern, D. Addgene: p{CFD4-3xP3::DsRed}. Available at: <https://www.addgene.org/86864/>.
102 (Accessed: 26th February 2020)

103

104